The Potential Benefit of Metformin to Reduce Delirium Risk and Mortality

1 views

|

December 6, 2022

Aging-US published this research paper in Volume 14, Issue 22, entitled, "The potential benefit of metformin to reduce delirium risk and mortality: a retrospective cohort study" by researchers from Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Palo Alto, CA; University of Iowa Carver College of Medicine, Department of Psychiatry, Iowa City, IA; Tottori University Faculty of Medicine, Department of Neuropsychiatry, Yonago-Shi, Tottori, Japan; University of Iowa Carver College of Medicine, Department of Emergency Medicine, Iowa City, IA; University of Iowa College of Public Health, Department of Biostatistics, Iowa City, IA; University of Iowa Carver College of Medicine, Department of Internal Medicine, Iowa City, IA. #openaccess #aging #metformin #mortality #researchpaper #peerreview #openscience #delirium #diabetes DOI - https://doi.org/10.18632/aging.204393 Corresponding author - Gen Shinozaki - gens@stanford.edu Abstract Purpose: Metformin has been reported to improve age-related disorders, including dementia, and to lower mortality. This study was conducted to investigate whether metformin use lower delirium risk, as well as long-term mortality. Methods: In this retrospective cohort study, previously recruited 1,404 subjects were analyzed. The relationship between metformin use and delirium, and the relationship between metformin use and 3-year mortality were investigated. Main findings: 242 subjects were categorized into a type 2 diabetes mellitus (DM)-without-metformin group, and 264 subjects were categorized into a DM-with-metformin group. Prevalence of delirium was 36.0% in the DM-without-metformin group, and 29.2% in the DM-with-metformin group. A history of metformin use reduced the risk of delirium in patients with DM (OR, 0.50 [95% CI, 0.32 to 0.79]) after controlling for confounding factors. The 3-year mortality in the DM-without-metformin group (survival rate, 0.595 [95% CI, 0.512 to 0.669]) was higher than in the DM-with-metformin group (survival rate, 0.695 [95% CI, 0.604 to 0.770]) (p=0.035). A history of metformin use decreased the risk of 3-year mortality after adjustment for confounding factors (HR, 0.69 [95% CI, 0.48 to 0.98]). Conclusions: Metformin use may lower the risk of delirium and mortality in DM patients. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204393 Keywords - delirium, metformin, diabetes mellitus, mortality, aging About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

BioprocessingDrug DiscoveryImaging/MicroscopyNeuroscience

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.